Sensei Biotherapeutics, Inc. announced two key promotions within the company's senior management team. Erin Colgan has been appointed to chief financial officer. Robert Pierce has been appointed chief research & development officer and will have additional responsibility for drug discovery, translational medicine, and clinical development of Sensei's pipeline programs. Erin Colgan joined Sensei Biotherapeutics in 2020 and has been responsible for all accounting, finance, and business functions.

Previously, Ms. Colgan was the vice president of financial and commercial planning and analysis at Intarcia Therapeutics, running the annual budgeting process as well as helping the company to prepare for a potential launch of their Type II diabetes product. She also held various accounting and finance roles of increasing responsibility over a nine-year career at Vertex Pharmaceuticals, including European Controller supporting the launch of their global cystic fibrosis franchise, overseeing the company-wide annual budgeting process, and several years leading the global commercial planning process.? Ms. Colgan began her career in public accounting at PwC where she worked in both audit and business development.